Molecular dynamics simulations and novel drug discovery
X Liu, D Shi, S Zhou, H Liu, H Liu… - Expert opinion on drug …, 2018 - Taylor & Francis
Introduction: Molecular dynamics (MD) simulations can provide not only plentiful dynamical
structural information on biomacromolecules but also a wealth of energetic information …
structural information on biomacromolecules but also a wealth of energetic information …
The importance of ongoing international surveillance for Creutzfeldt–Jakob disease
N Watson, JP Brandel, A Green, P Hermann… - Nature Reviews …, 2021 - nature.com
Creutzfeldt–Jakob disease (CJD) is a rapidly progressive, fatal and transmissible
neurodegenerative disease associated with the accumulation of misfolded prion protein in …
neurodegenerative disease associated with the accumulation of misfolded prion protein in …
Extracellular vesicles–propagators of neuropathology and sources of potential biomarkers and therapeutics for neurodegenerative diseases
Neurodegenerative diseases are characterised by the irreversible degeneration of neurons
in the central or peripheral nervous systems. These include amyotrophic lateral sclerosis …
in the central or peripheral nervous systems. These include amyotrophic lateral sclerosis …
Neuroimaging in dementia
AM Staffaroni, FM Elahi, D McDermott… - Seminars in …, 2017 - thieme-connect.com
Although the diagnosis of dementia still is primarily based on clinical criteria, neuroimaging
is playing an increasingly important role. This is in large part due to advances in techniques …
is playing an increasingly important role. This is in large part due to advances in techniques …
Genetic PrP prion diseases
MO Kim, LT Takada, K Wong… - Cold Spring …, 2018 - cshperspectives.cshlp.org
Genetic prion diseases (gPrDs) caused by mutations in the prion protein gene (PRNP) have
been classified as genetic Creutzfeldt–Jakob disease, Gerstmann–Sträussler–Scheinker …
been classified as genetic Creutzfeldt–Jakob disease, Gerstmann–Sträussler–Scheinker …
Age at onset in genetic prion disease and the design of preventive clinical trials
EV Minikel, SM Vallabh, MC Orseth, JP Brandel… - Neurology, 2019 - AAN Enterprises
Objective To determine whether preventive trials in genetic prion disease could be designed
to follow presymptomatic mutation carriers to onset of disease. Methods We assembled age …
to follow presymptomatic mutation carriers to onset of disease. Methods We assembled age …
[HTML][HTML] Genetic counseling for prion disease: updates and best practices
JS Goldman, SM Vallabh - Genetics in Medicine, 2022 - Elsevier
Prion disease is a rare, fatal, and often rapidly progressive neurodegenerative disease. Ten
to fifteen percent of cases are caused by autosomal dominant gain-of-function variants in the …
to fifteen percent of cases are caused by autosomal dominant gain-of-function variants in the …
Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases
Genetic prion diseases are a rare and diverse group of fatal neurodegenerative disorders
caused by pathogenic sequence variations in the prion protein gene, PRNP. Data on CSF …
caused by pathogenic sequence variations in the prion protein gene, PRNP. Data on CSF …
Fatal familial insomnia and sporadic fatal insomnia
L Cracco, BS Appleby, P Gambetti - Handbook of clinical neurology, 2018 - Elsevier
Fatal familial insomnia (FFI) and sporadic fatal insomnia (sFI), or thalamic form of sporadic
Creutzfeldt–Jakob disease MM2 (sCJDMM2T), are prion diseases originally named and …
Creutzfeldt–Jakob disease MM2 (sCJDMM2T), are prion diseases originally named and …
Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease
Background Prion disease is neurodegenerative disease that is typically fatal within months
of first symptoms. Clinical trials in this rapidly declining symptomatic patient population have …
of first symptoms. Clinical trials in this rapidly declining symptomatic patient population have …